Researchers in Thailand discovered that people with advanced liver disease who develop liver cancer have different gut bacteria compared to those with liver disease alone. By studying the bacteria in stool samples from healthy people, patients with cirrhosis (scarring of the liver), and patients with liver cancer, scientists found that cancer patients had fewer types of bacteria and different bacterial populations. These changes appear to affect how the intestines work and trigger inflammation in the body. This discovery suggests that examining gut bacteria composition might help doctors identify which liver disease patients are at highest risk for developing cancer.
The Quick Take
- What they studied: Whether the types and amounts of bacteria living in the gut differ between people with liver cirrhosis who do or don’t have liver cancer
- Who participated: 107 Thai adults divided into three groups: 30 healthy people with normal livers, 33 people with cirrhosis (scarred livers) but no cancer, and 44 people with both cirrhosis and liver cancer
- Key finding: People with liver cancer and cirrhosis had significantly fewer types of gut bacteria and different bacterial populations compared to healthy people and those with cirrhosis alone. They also had reduced levels of bacteria that produce a beneficial compound called butyrate, and showed signs of increased intestinal leakiness and inflammation.
- What it means for you: If you have liver cirrhosis, changes in your gut bacteria might indicate increased risk for developing liver cancer. This research suggests that gut bacteria analysis could potentially become a tool to help doctors identify high-risk patients, though more research is needed before this can be used clinically.
The Research Details
This was a cross-sectional study, meaning researchers collected information from all participants at one point in time rather than following them over years. Scientists collected stool samples from three groups of Thai adults and analyzed the bacteria using a genetic sequencing technique called 16S rRNA sequencing, which identifies different bacterial species by reading their genetic code. They also measured markers of intestinal health in blood samples and looked at genes related to butyrate production, a beneficial compound made by certain bacteria.
The researchers compared the bacterial communities between the three groups to see which types of bacteria were more or less common in each group. They also predicted what functions these bacteria might perform based on their genetic makeup, looking at pathways involved in metabolism and other processes. Additionally, they measured inflammation markers in the blood to understand how the immune system was responding.
Understanding how gut bacteria change in liver disease is important because the bacteria in our intestines affect how our immune system works and how our intestines function. When bacteria populations change (called dysbiosis), it can lead to increased inflammation and intestinal leakiness, which may contribute to disease progression. By studying a Southeast Asian population specifically, researchers can identify patterns that may be unique to this region and help doctors in these areas better understand and potentially prevent liver cancer.
This study has several strengths: it compared three well-defined groups (healthy, cirrhosis, and cancer), used modern genetic sequencing technology, and measured multiple related factors (bacteria, intestinal markers, and inflammation). However, as a cross-sectional study, it shows associations but cannot prove that bacterial changes cause cancer—only that they occur together. The sample size is moderate (107 people total), which is reasonable for this type of research but limits how broadly results apply. The study was conducted in Thailand, so findings may be most relevant to Southeast Asian populations.
What the Results Show
The most striking finding was that people with liver cancer and cirrhosis had significantly lower bacterial diversity—meaning fewer different types of bacteria—compared to healthy people and those with cirrhosis alone. This reduction in diversity is important because a healthy gut typically has many different bacterial species working together.
Specific bacterial changes were also observed: certain bacteria (Ligilactobacillus, Catenibacterium, and Alloprevotella) were more common in people with cirrhosis alone, while people with cancer had increased amounts of Ruminococcus gnavus and decreased amounts of bacteria that produce butyrate, a beneficial compound that helps maintain intestinal health.
People with liver cancer also showed signs of ’leaky gut’—meaning their intestinal barrier wasn’t working as well. Blood markers indicating intestinal damage (I-FABP and LBP) were significantly elevated in cancer patients compared to both healthy controls and cirrhosis-only patients. Additionally, genes responsible for processing butyrate were less active in cancer patients, suggesting reduced production of this protective compound.
Finally, cancer patients showed elevated levels of multiple inflammation-promoting substances in their blood, including GM-CSF, IL-10, IL-18, IL-1α, IL-7, IL-8, and M-CSF. This suggests their immune systems were in a heightened inflammatory state.
The study also revealed differences in bacterial metabolic pathways between groups. Bacteria in cancer patients showed altered patterns in folate metabolism, sulfur metabolism, tyrosine metabolism, and steroid biosynthesis—all processes that affect how the body functions. These pathway differences suggest that cancer patients’ bacterial communities may be functioning differently at a molecular level, not just in terms of which species are present.
Previous research has shown that gut bacteria play important roles in liver disease, but most studies have focused on European or Asian populations without specifically examining Southeast Asian cohorts. This study adds important regional data and confirms findings from other populations that dysbiosis (unhealthy bacterial imbalance) is associated with more severe liver disease. The finding that reduced butyrate-producing bacteria correlates with cancer risk aligns with previous research suggesting butyrate’s protective effects on intestinal health and immune function.
This study has important limitations to consider. Because it’s cross-sectional, we cannot determine whether bacterial changes cause cancer or result from having cancer—the relationship could go both directions. The sample size, while adequate, is relatively modest, which means results may not apply equally to all populations. The study was conducted only in Thailand, so findings may not directly apply to other regions with different populations and dietary patterns. Additionally, the study didn’t account for factors like diet, medications, or other lifestyle factors that could influence gut bacteria. Finally, this is observational research showing associations, not proof of cause-and-effect relationships.
The Bottom Line
For people with liver cirrhosis: While this research is promising, it’s too early to make specific recommendations based on these findings alone. However, it suggests that monitoring gut health through dietary choices that support beneficial bacteria (like eating fiber-rich foods) may be worthwhile. Discuss with your doctor whether probiotic supplements or dietary modifications might be appropriate for your situation. For healthcare providers: This research suggests that analyzing gut bacteria composition could potentially become a useful tool for identifying cirrhosis patients at higher risk for developing liver cancer, though more research is needed before implementing this clinically.
This research is most relevant to people with liver cirrhosis, particularly those in Southeast Asia, as it may help identify who is at higher risk for developing liver cancer. Healthcare providers treating liver disease patients should be aware of these findings. People with healthy livers don’t need to be concerned about these specific bacterial changes. However, the research highlights the general importance of maintaining healthy gut bacteria for everyone.
If dietary or probiotic interventions were to be developed based on this research, benefits would likely take weeks to months to appear, as it takes time for gut bacteria populations to change and for their effects on inflammation and intestinal health to become apparent. However, this research is still in the discovery phase, and clinical applications are likely years away.
Want to Apply This Research?
- For users with cirrhosis: Track daily fiber intake (target 25-30 grams) and note any digestive symptoms (bloating, changes in bowel movements, abdominal discomfort) weekly. If probiotic supplements are recommended by your doctor, log which ones you’re taking and any changes you notice in digestion or energy levels.
- Users with cirrhosis could use the app to set reminders for consuming fiber-rich foods (vegetables, whole grains, legumes) that support beneficial gut bacteria. The app could provide recipes and shopping lists for foods that promote healthy bacterial populations, and track consistency with these dietary changes over time.
- Establish a baseline of current digestive health and dietary patterns, then monitor changes monthly. If users have access to medical testing, track any changes in inflammation markers or intestinal permeability markers over time. Create alerts for concerning symptoms (severe abdominal pain, changes in stool color or consistency) that warrant medical attention.
This research describes associations between gut bacteria changes and liver cancer in a specific population and does not establish cause-and-effect relationships. These findings are preliminary and should not be used to diagnose, treat, or prevent liver cancer. If you have liver cirrhosis or are concerned about liver cancer risk, consult with your healthcare provider about appropriate screening and management strategies. Do not start, stop, or change any medications or supplements without discussing with your doctor first. This information is for educational purposes only and is not a substitute for professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.